EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study

Pablo Garcia-Pavia, Marla B Sultan, Balarama Gundapaneni, Yoshiki Sekijima, Federico Perfetto, Mazen Hanna, Ronald Witteles

JACC: Heart Failure · 2024-01 · 12 (1) · 150-160

DOI: 10.1016/j.jchf.2023.08.032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Heart Failure, 2024-01. Verfasst von Pablo Garcia-Pavia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV, Madrid, Spain; Centro Nacional de Investigaciones Cardiovasculares (CNIC), Ma…. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies, Heart Failure. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Tafamidis was approved to treat patients with transthyretin amyloid cardiomyopathy (ATTR-CM) on the basis of findings from the phase 3 Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT). OBJECTIVES: This study was a post hoc analysis exploring tafamidis efficacy in octogenarian patients. METHODS: Analysis of patients aged

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialCardiomyopathiesHeart FailureAgedAged, 80 and overHumansOctogenariansPrealbuminClinical Trials, Phase III as TopicBenzoxazoles

Stichwörter der Autor:innen

ageamyloidosiselderlyheart failure with preserved ejection fractionsurvival

Substanzen

PrealbumintafamidisBenzoxazoles

Autor:innen und Institutionen

  • Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV, Madrid, Spain; Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Universidad Francisco de Vitoria (UFV), Pozuelo de Alarcó…
  • Pfizer Inc, New York, New York, USA.
  • Pfizer Inc, Groton, Connecticut, USA.
  • Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan.
  • Tuscan Regional Amyloid Referral Centre, Careggi University Hospital, Florence, Italy.
  • Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.

Förderung

  • Pfizer

Zitieren

APA

Garcia-Pavia, P., Sultan, M. B., Gundapaneni, B., Sekijima, Y., Perfetto, F., Hanna, M., & Witteles, R. (2024). Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study. JACC: Heart Failure, 12(1), 150-160. https://doi.org/10.1016/j.jchf.2023.08.032

Vancouver

Garcia-Pavia P, Sultan MB, Gundapaneni B, Sekijima Y, Perfetto F, Hanna M, et al. Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study. JACC: Heart Failure. 2024;12(1):150-160. doi:10.1016/j.jchf.2023.08.032

BibTeX
@article{GarciaPavia2024,
  author = {Garcia-Pavia, Pablo and Sultan, Marla B and Gundapaneni, Balarama and Sekijima, Yoshiki and Perfetto, Federico and Hanna, Mazen and Witteles, Ronald},
  title = {Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study},
  journal = {JACC: Heart Failure},
  year = {2024},
  volume = {12},
  number = {1},
  pages = {150--160},
  doi = {10.1016/j.jchf.2023.08.032}
}
Kostenlos starten →